ASCO: Pembrolizumab superior for initial Tx of advanced NSCLC 06-04-2018 James Health Problems (HealthDay)—For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced Read more
Adjuvant pembrolizumab beneficial in stage III melanoma 04-16-2018 James Health Problems (HealthDay)—Pembrolizumab is associated with significantly longer recurrence-free survival than placebo Read more